Augmentation of Thrombin Generation in Neonates Undergoing Cardiopulmonary Bypass
We compared recombinant activated factor VII (rFVIIa) with three-factor prothrombin complex concentrate (3F-PCC) for the ability to augment thrombin generation (TG) in neonatal plasma after cardiopulmonary bypass (CPB).
Augmentation of Thrombin Generation in Neonates Undergoing Cardiopulmonary Bypass
We compared recombinant activated factor VII (rFVIIa) with three-factor prothrombin complex concentrate (3F-PCC) for the ability to augment thrombin generation (TG) in neonatal plasma after cardiopulmonary bypass (CPB).
Comparison Between Five-Year Mortality of Patients With and Without Red Blood Cell Transfusion after Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction
This study evaluates the long-term impact on the prognosis of patients who received a RBC transfusion after PCI for the treatment of ST-segment elevation MI (STEMI).
Morbidity But Not Mortality Is Decreased After Off-Pump Coronary Artery Bypass Surgery
This retrospective study compared outcomes between on-pump and off-pump CABG from a large multicenter cohort of propensity-matched patients.
Identification of Modifiable Risk Factors for Acute Kidney Injury after Coronary Artery Bypass Graft Surgery in an Asian Population
We aimed to ascertain whether the lowest hematocrit during CPB, preoperative anemia, and intraoperative transfusion remained as independent modifiable risk factors associated with AKI in our prospective cohort of Asians.
Red Blood Cell Transfusion: What is the Evidence When to Transfuse?
A restrictive transfusion strategy of administering red blood cell transfusion in patients with hemoglobin concentration of 7-8 g/dl in most patients is supported by randomized clinical trials.
Safety and Effects of Two Red Blood Cell Transfusion Strategies in Pediatric Cardiac Surgery Patients: A Randomized Controlled Trial
For patients with a non-cyanotic congenital heart defect undergoing elective cardiac surgery, a restrictive RBC transfusion policy (threshold of Hb 8.0 g/dl) during the entire perioperative period is safe, leads to a shorter hospital stay and is less expensive.
Is Dilutional Coagulopathy Induced by Different Colloids Reversible by Replacement of Fibrinogen and Factor XIII Concentrates?
Coagulation and platelet function are impaired by all 3 colloids.
Enhancing Intervertebral Disc Repair and Regeneration Through Biology: Platelet-Rich Plasma as an Alternative Strategy
This review describes the current understanding of intervertebral disc degeneration (IDD) and related biological therapeutic strategies, especially the promising prospects of PRP treatment.
Comparison of Two Doses of Tranexamic Acid in Adults Undergoing Cardiac Surgery with Cardiopulmonary Bypass
The optimal dose of tranexamic acid (TA) is still an issue. The authors compared two doses of TA during cardiac surgery in a multicenter, double-blinded, randomized study.
Combined Treatment of Ulinastatin and Tranexamic Acid Provides Beneficial Effects by Inhibiting Inflammatory and Fibrinolytic Response in Patients Undergoing Heart Valve Replacement Surgery
We investigated the effect of ulinastatin and tranexamic acid administered alone or in combination on inflammatory cytokines and fibrinolytic system in patients undergoing heart valve replacement surgery during cardiopulmonary bypass (CPB).
The Biomechanics and Histological Effects of Platelet-Rich Plasma on Fracture Healing
Platelet-rich plasma (PRP) includes growth factors and proteins that accelerate and stimulate bone regeneration and tissue recovery. The aim of this study was to evaluate the effects of PRP on fracture healing in terms of biomechanics and histology.